EVFM - Evofem Biosciences announces proposed public offering

Evofem Biosciences (NASDAQ:EVFM) on Thursday announced an underwritten public offering of shares (or pre-funded warrants to purchase stock) and warrants. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms. Net proceeds will be used for continuation of commercialization activities related to its Phexxi vaginal gel, continuation of its registrational phase 3 clinical trial Evoguard - which is evaluating Phexxi for prevention of chlamydia and gonorrhea in women - and related development activities, and general corporate purposes.

For further details see:

Evofem Biosciences announces proposed public offering